1. Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care . 2011;17(suppl 8):S235-S248.
2. Gibson A, Degenhardt L, Mattick RP, et al. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction . 2008;103:462-468. doi: 10.1111/j.1360-0443.2007.02090.x
3. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results From the 2020 National Survey on Drug Use and Health . HHS Publication PEP21-07-01-003, NSDUH Series H-56. 2021. Accessed March 19, 2023. www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf
4. Haffajee RL, Andraka-Christou B, Attermann J, et al. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy . 2020;15:69. doi: 10.1186/s13011-020-00312-3
5. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect . 2002;1:13-20. doi: 10.1151/spp021113
6. Koob GF. Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry . 2020;87:44-53. doi: 10.1016/j.biopsych.2019.05.023
7. Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. For Health care and Addiction Professionals, Policymakers, Patients, and Families . Treatment Improvement Protocol TIP 63. Publication No. PEP21-02-01-002. 2021. Accessed March 19, 2023. https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf
8. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ . 2017;357:j1550. doi: 10.1136/bmj.j1550
9. Korownyk C, Perry D, Ton J, et al. Opioid use disorder in primary care: PEER umbrella systematic review of systematic reviews. Can Fam Physician . 2019;65:e194-e206.
10. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev . 2009;(3):CD002209. doi: 10.1002/14651858.CD002209.pub2
11. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev . 2014;(2):CD002207. doi: 10.1002/14651858.CD002207.pub4
12. Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet . 2011;377:1506-1513. doi: 10.1016/S0140-6736(11)60358-9
13. Soyka M, Zingg C, Koller G, et al. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol . 2008;11:641-653. doi: 10.1017/S146114570700836X
14. Institute of Medicine Committee on Federal Regulation of Methadone Treatment; Rettig R, Yarmolinsky A, eds. Federal Regulation of Methadone Treatment . National Academies Press; 1995.
15. 42 eCFR §8. Medication assisted treatment for opioid use disorders. Revised March 15, 2023. Accessed March 23, 2023. www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-8?toc=1
16. Faggiano F, Vigna-Taglianti F, Versino E, et al. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev . 2003;(3):CD002208. doi: 10.1002/14651858.CD002208
17. Baxter LE Sr, Campbell A, Deshields M, et al. Safe methadone induction and stabilization: report of an expert panel. J Addict Med . 2013;7:377-386. doi: 10.1097/01.ADM.0000435321.39251.d7
18. Olfson M, Zhang VS, Schoenbaum M, et al. Trends in buprenorphine treatment in the United States, 2009-2018. JAMA . 2020;323:276-277. doi: 10.1001/jama.2019.18913
19. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther . 1994;55:569-580. doi: 10.1038/clpt.1994.71
20. Walley AY, Palmisano J, Sorensen-Alawad A, et al. Engagement and substance dependence in a primary care-based addiction treatment program for people infected with HIV and people at high-risk for HIV infection. J Subst Abuse Treat . 2015;59:59-66. doi: 10.1016/j.jsat.2015.07.007
21. Lagisetty P, Klasa K, Bush C, et al. Primary care models for treating opioid use disorders: what actually works? A systematic review. PloS One . 2017;12:e0186315. doi: 10.1371/journal.pone.0186315
22. Du CX, Shi J, Tetrault JM, et al. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Fam Pract . 2022;39:234-240. doi: 10.1093/fampra/cmab166
23. Herring AA, Vosooghi AA, Luftig J, et al. High-dose buprenorphine induction in the emergency department for treatment of opioid use disorder. JAMA Netw Open . 2021;4:e2117128. doi: 10.1001/jamanetworkopen.2021.17128
24. Hämmig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99-105. doi: 10.2147/SAR.S109919
25. Snyder H, Kalmin MM, Moulin A, et al. Rapid adoption of low-threshold buprenorphine treatment at California emergency departments participating in the CA Bridge Program. Ann Emerg Med . 2021;78:759-772. doi: 10.1016/j.annemergmed.2021.05.024
26. Wong JSH, Nikoo M, Westenberg JN, et al. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addict Sci Clin Pract . 2021;16:11. doi: 10.1186/s13722-021-00220-2
27. Lee JD, Vocci F, Fiellin DA. Unobserved “home” induction onto buprenorphine. J Addict Med . 2014;8:299-308. doi: 10.1097/ADM.0000000000000059
28. Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry . 2012;69:973-981. doi: 10.1001/archgenpsychiatry.2012.1a
29. Wolfe D, Carrieri MP, Dasgupta N, et al. Concerns about injectable naltrexone for opioid dependence. Lancet . 2011;377:1468-1470. doi: 10.1016/S0140-6736(10)62056-9
30. Tanum L, Solli KK, Latif ZEH, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine–naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry . 2017;74:1197-1205. doi: 10.1001/jamapsychiatry.2017.3206
31. Murphy SM, Polsky D, Lee JD, et al. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction . 2017;112:1440-1450. doi: 10.1111/add.13807
32. Ferrari A, Coccia CPR, Bertolini A, et al. Methadone—metabolism, pharmacokinetics and interactions. Pharmacol Res . 2004;50:551-559. doi: 10.1016/j.phrs.2004.05.002
33. 42 eCFR Part 2. Confidentiality of substance use disorder patient records. January 18, 2017. Accessed March 23, 2023. www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-2
34. Kao DP, Haigney MCP, Mehler PS, et al. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration. Addiction . 2015;110:1468-1475. doi: 10.1111/add.13013
35. Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing . Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation . 2020;142:e214-e233. doi: 10.1161/CIR.0000000000000905
36. Leshner AI, Mancher M, eds. Barriers to broader use of medications to treat opioid use disorder. In: Medications for Opioid Use Disorder Save Lives . National Academies Press; 2019:109-136.
37. Chilcoat HD, Amick HR, Sherwood MR, et al. Buprenorphine in the United States: Motives for abuse, misuse, and diversion. J Subst Abuse Treat . 2019;104:148-157. doi: 10.1016/j.jsat. 2019.07.005
38. Qato DM, Daviglus ML, Wilder J, et al. “Pharmacy deserts” are prevalent in Chicago’s predominantly minority communities, raising medication access concerns. Health Aff (Millwood) . 2014;33:1958-1965. doi: 10.1377/hlthaff.2013.1397
39. Mason M, Soliman R, Kim HS, et al. Disparities by sex and race and ethnicity in death rates due to opioid overdose among adults 55 years or older, 1999 to 2019. JAMA Netw Open . 2022;5:e2142982. doi: 10.1001/jamanetworkopen.2021.42982
40. Rosenblum A, Cleland CM, Fong C, et al. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health . 2011;2011:948789. doi: 10.1155/2011/948789
41. Chan B, Hoffman KA, Bougatsos C, et al. Mobile methadone medication units: a brief history, scoping review and research opportunity. J Subst Abuse Treat . 2021;129:108483. doi: 10.1016/j.jsat.2021.108483
42. Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med . 2020;14:95-98. doi: 10.1097/ADM.0000000000000555
43. Messmer SE, Elmes AT, Jimenez AD, et al. Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago. J Subst Use Addict Treat . 2023;209054. doi: 10.1016/j.josat.2023.209054
